qXR-CTR vs ElucidVivo A.3
AI Verdict
Choose qXR-CTR if…
Choose qXR-CTR if you need an efficient, AI-powered solution for automated cardiothoracic ratio measurement from standard chest X-rays. This tool is ideal for initial screening programs or high-volume settings where rapid assessment of heart size and potential heart failure risk is crucial. It provides a quick, objective metric to flag patients who may require further cardiac evaluation.
View qXR-CTR →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability from CT angiography images. This system is best suited for stratifying patients with atherosclerosis, optimizing treatment decisions, and monitoring disease progression by providing granular insights into plaque characteristics validated against histology. It offers advanced visualization and measurement capabilities for complex cardiovascular disease management.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | qXR-CTR | ElucidVivo A.3 |
|---|---|---|
| Deployment | Can be deployed on cloud or on-premise. The Qure.ai app receives DICOM studies via DICOM network protocol from medical systems (PACS/Modality) or can import DICOM from the local system. The received DICOM study is processed in Qure's cloud server, and AI-processed reports are displayed on the app. | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
qXR-CTRTool A (qXR-CTR) emphasizes automation of a single, common metric (CTR) from chest X-rays, aiming for rapid and efficient diagnoses with seamless integration into existing radiology workflows. It provides annotated X-rays and structured reports, supporting a streamlined user experience. Tool B offers more complex visualization and interactive analysis, which, while powerful, may imply a steeper learning curve compared to Tool A's focus on automated simplicity.
Clinical Value
ElucidVivo A.3Tool B (ElucidVivo A.3) offers a more profound clinical value by providing quantitative analysis of arterial plaque composition and stability, validated against histology, and deriving fractional flow reserve (FFRct). This enables advanced patient stratification and optimizes treatment decisions for atherosclerosis, offering deeper, more specific insights. Tool A provides valuable, rapid screening for heart failure risk by assessing CTR and pleural effusion, but its scope is less detailed than Tool B's comprehensive plaque characterization.
Pricing & Value
TieBoth tools require direct contact for pricing, indicating a similar level of pricing transparency (or lack thereof). However, both demonstrate a clear path to value realization through established reimbursement mechanisms: Tool A's products are billable under CMS-issued CPT codes, and Tool B has announced broad reimbursement with a new Category I CPT designation. Without specific pricing details, a definitive winner cannot be determined.
Enterprise Readiness
qXR-CTRTool A (qXR-CTR) explicitly states HIPAA compliance, BAA availability, and flexible deployment options (cloud, on-premise, hybrid) in its published specifications and confirmed by search results. While Tool B (ElucidVivo A.3) also indicates FDA clearance, PACS/EMR integration, and 'SOC 2 / HIPAA-aligned data protection,' Tool A's explicit declarations in the initial facts provide a stronger, more immediate signal of enterprise readiness.
Innovation
ElucidVivo A.3Tool B (ElucidVivo A.3) demonstrates higher innovation by offering quantitative analysis of arterial plaque composition and stability, validated against histology, and deriving FFRct from CT angiography. This 'CT Virtual Histologyu2122' provides deeper, more novel insights into disease pathology beyond simple measurements. Tool A automates the measurement of a well-established metric (CTR), which is valuable but less groundbreaking in its approach.
Support & Docs
qXR-CTRTool A (Qure.ai) explicitly mentions the availability of 'Qure.ai Documentation' and a 'Qure.ai App User's Manual,' along with offering local and multilingual support. For Tool B (ElucidVivo A.3), specific details regarding support resources or comprehensive documentation are not readily available in the provided information or search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | qXR-CTR | ElucidVivo A.3 |
|---|---|---|
| Name | qXR-CTR | ElucidVivo A.3 |
| Company | Qure.ai Technologies | Elucid Bioimaging |
| Primary Function | Automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk. | Provides quantitative analysis of arterial plaque composition and stability from CT angiography, assisting in atherosclerosis patient stratification and optimizing treatment decisions. |
| Target Imaging Modality | Chest X-ray images | CT angiography |
| Key Analytical Focus | Cardiothoracic ratio (CTR) measurement | Quantitative analysis of arterial plaque composition (Lipid-Rich Necrotic Core (LRNC), matrix, calcifications) and fractional flow reserve (FFRct). |
Videos
Demos, reviews, and walkthroughs featuring qXR-CTR and ElucidVivo A.3.